The Community-acquired Bacterial Pneumonia Market Is Expected To Witness Growth At A Minimal CAGR of 0.79% In The 7MM During The Study Period (2019-32)

The dynamics of the Community-acquired Bacterial Pneumonia market are anticipated to change in the coming years owing to the launch of upcoming therapies along with the rise in the number of cases and healthcare spending across the world.

LAS VEGAS, March 15, 2022 /PRNewswire/ -- DelveInsight's Community-acquired Bacterial Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, Community-acquired Bacterial Pneumonia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Takeaways from the Community-acquired Bacterial Pneumonia Market

• As per DelveInsight's estimates, the Community-acquired Bacterial Pneumonia market size is expected to reach USD 2,866 million by 2032.
• As per DelveInsight's estimates, the total CABP incident cases is expected to be approx 6.9 million cases in the 7MM, which is further anticipated to increase by 2032.
• Key Community-acquired Bacterial Pneumonia companies including Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, and others are having approved products for the treatment of patients affected with CABP and some of them are currently working to improve the treatment paradigm of CABP.
• The Community-acquired Bacterial Pneumonia therapies in the pipeline include CAL02, Cx611, and others.
• The key driver for the surge in Community-Acquired Bacterial Pneumonia market size is the rise in the number of incident cases in the 7MM.

Discover more about therapies set to grab major Community-acquired Bacterial Pneumonia market share @ Community-acquired Bacterial Pneumonia Market Landscape

Community-acquired Bacterial Pneumonia Overview

Community-acquired Bacterial Pneumonia (CABP) is a common, severe infection of the lung parenchyma. It is a leading cause of death in adults. It is one of the most common respiratory diseases among the various infections that cause sepsis. Community-acquired Bacterial Pneumonia most commonly caused by Streptococcus pneumoniae in adults worldwide. Haemophilus influenzae and Mycoplasma pneumoniae are two other common bacteria that cause Community-acquired Pneumonia (CAP). Chlamydia and mycoplasma pneumonia is frequently clinically indistinguishable from other types of pneumonia.

The CABP symptoms include malaise, chills, rigor, fever, cough, dyspnea, and chest pain. Coughing is usually productive in older children and adults but dry in infants, young children, and the elderly. Dyspnea is usually mild and exertional, and it is almost never present at rest.

Community-acquired Bacterial Pneumonia Epidemiology Segmentation

As per DelveInsight analysis, the total incident cases of CABP infection were approx 6.9 million cases in the 7MM which are anticipated to be increased by 2032.

Among EU5 countries, Germany had the highest number of CABP incident cases in 2019.

The Community-acquired Bacterial Pneumonia Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

• Incident Cases of CABP
• Incident Cases of CABP based on Gender
• Incident Cases of CABP based on Severity
• Incident Cases of CABP based on Pathogens
• Incident Cases of CABP based on Age

Download report to understand which factors are driving CABP infection epidemiology trends @ Community-acquired Bacterial Pneumonia Epidemiological Insights

Community-acquired Bacterial Pneumonia Market

Although the majority of patients with Community-acquired Pneumonia are treated empirically, but the best treatment option remains unknown. The antibiotics govern the Community-Acquired Bacterial Pneumonia treatment landscape. Nuzyra (omadacycline), Baxdela (delafloxacin), and Xenleta (lefamulin) are some of the drugs approved for the Community-Acquired Bacterial Pneumonia treatment. In addition, Recarbrio (Cilastatin/imipenem/relebactam), Fetroja (cefiderocol), Avycaz (ceftazidime-avibactam), Vibativ (telavancin), and Zerbaxa (ceftolozane + tazobactam) are among the drugs approved for hospital-acquired/ventilator-associated bacterial pneumonia (HABP). 

Moreover, in individuals 18 years of age and older, a vaccine such as Vaxneuvance is recommended for active immunization to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae.

Furthermore, Community-acquired Pneumonia treatment has become difficult due to changing safety profiles and efficacy of well-established antibiotics, as well as a lack of new therapeutic options.

Discover more about therapy set to grab substantial Community-acquired Bacterial Pneumonia market share @ Community-acquired Bacterial Pneumonia Treatment 

Community-acquired Bacterial Pneumonia Pipeline Therapies and Key Players

• CAL02: Eagle Pharmaceutical Inc/Combioxin SA
• Cx611: Takeda

To know about more Community-acquired Bacterial Pneumonia developing drugs for treatment visit @ Community-acquired Bacterial Pneumonia Treatment Outlook 

Community-acquired Bacterial Pneumonia Market Dynamics

The dynamics of the Community-Acquired Bacterial Pneumonia market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Furthermore, the surge in the rise in the number of incident cases of Community-Acquired Bacterial Pneumonia will also contribute to the Community-Acquired Bacterial Pneumonia market growth. In addition, the expected launch of drugs in the pipeline will fuel the Community-Acquired Bacterial Pneumonia market size.

However, an already saturated market with various approved candidates and varying etiology of the disease will hinder the Community-acquired Bacterial Pneumonia market growth. Furthermore, unreported and undiagnosed cases, as well as lack of awareness about the disease, might also serve as potential barriers for the Community-acquired Bacterial Pneumonia market.

Scope of the Community-acquired Bacterial Pneumonia Market Report

• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Community-acquired Pneumonia Companies: Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, and others
• Key Pipeline Therapies: CAL02, Cx611, and others
• Therapeutic Assessment: Community-acquired Pneumonia current marketed and emerging therapies
• Community-acquired Bacterial Pneumonia Market Dynamics: Community-acquired Bacterial Pneumonia market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Community-acquired Bacterial Pneumonia Market Access and Reimbursement

Discover more about the future Community-acquired Bacterial Pneumonia market share of treatment therapies @ Community-acquired Bacterial Pneumonia Treatment Market

Table of Contents 

Get in touch with our Business executive @ Healthcare Due Diligence Services 

Related Reports

Community-acquired Bacterial Pneumonia Epidemiology

Community-acquired Bacterial Pneumonia Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Community-acquired Bacterial Pneumonia epidemiology in the 7MM.

Community-acquired Bacterial Pneumonia Pipeline

Community-acquired Bacterial Pneumonia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Community-acquired Bacterial Pneumonia companies involved such as Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, among others.

Community-acquired Pneumonia Pipeline 

Community-acquired Pneumonia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Community-acquired Pneumonia companies involved such as Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, among others.

Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market

Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Hospital-acquired and Ventilator-associated Bacterial Pneumonia companies such as Duke University, Sinovent Pty Ltd., Cumberland Pharmaceuticals, among others.

Bacterial Pneumonia Market

Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Bacterial Pneumonia companies such as Shionogi, Merck Sharp & Dohme Corp., among others.

Pneumonia Market

Pneumonia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Pneumonia companies such as Pfizer, Affinivax, Merck Sharp &Dohme Corp., Vaxcyte, among others.

Nosocomial Pneumonia Pipeline

Nosocomial Pneumonia Pipeline Insight, 2022 report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Nosocomial Pneumonia companies involved such as Merck & Co, Clarametyx Biosciences, Aridis Pharmaceuticals, Clarametyx Biosciences, Nabriva Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg